{"id":"il6","name":"Interleukin-6 and IL-6 receptor","symbol":"IL6, IL6R","route":"/targets/il6/","asOf":"2026-09-10","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6018","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000136244","uniprot":"https://www.uniprot.org/uniprotkb/P05231/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/P05231","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL1795129","open-targets":"https://platform.opentargets.org/target/ENSG00000136244","civic":"https://civicdb.org/genes/3569/summary","oncokb":"https://www.oncokb.org/gene/IL6","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=IL6","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=IL6","depmap":"https://depmap.org/portal/gene/IL6?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000136244-IL6","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/3569","omim":"https://www.omim.org/entry/147620"},{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6019","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000160712","uniprot":"https://www.uniprot.org/uniprotkb/P08887/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/P08887","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL2364155","open-targets":"https://platform.opentargets.org/target/ENSG00000160712","civic":"https://civicdb.org/genes/3570/summary","oncokb":"https://www.oncokb.org/gene/IL6R","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=IL6R","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=IL6R","depmap":"https://depmap.org/portal/gene/IL6R?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000160712-IL6R","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/3570","omim":"https://www.omim.org/entry/147880"}],"products":[{"id":"siltuximab","name":"Siltuximab","status":"approved","modality":"Monoclonal antibody (anti-IL-6, chimeric IgG1)","route":"/drugs/siltuximab/"},{"id":"tocilizumab","name":"Tocilizumab","status":"approved","modality":"Monoclonal antibody (anti-IL-6 receptor, humanised IgG1)","route":"/drugs/tocilizumab/"}],"trials":[{"id":"nct06084936","name":"A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma","nct":"NCT06084936","phase":"3","status":"recruiting"},{"id":"nct07570173","name":"A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)","nct":"NCT07570173","phase":"2/3","status":"recruiting"},{"id":"nct04980222","name":"A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma","nct":"NCT04980222","phase":"2","status":"active"},{"id":"nct07589634","name":"A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relaps","nct":"NCT07589634","phase":"2","status":"recruiting"},{"id":"nct05207670","name":"A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies","nct":"NCT05207670","phase":"2","status":"active"},{"id":"nct06679829","name":"A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant","nct":"NCT06679829","phase":"2","status":"recruiting"},{"id":"nct03315026","name":"Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis","nct":"NCT03315026","phase":"2","status":"active"},{"id":"nct05846789","name":"Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers","nct":"NCT05846789","phase":"2","status":"recruiting"},{"id":"nct03075696","name":"A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treat","nct":"NCT03075696","phase":"1/2","status":"active"},{"id":"nct05535244","name":"A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multi","nct":"NCT05535244","phase":"1/2","status":"active"},{"id":"nct04524871","name":"A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Li","nct":"NCT04524871","phase":"1/2","status":"active"},{"id":"nct05583617","name":"A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma","nct":"NCT05583617","phase":"1/2","status":"recruiting"},{"id":"nct04246086","name":"A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokineti","nct":"NCT04246086","phase":"1/2","status":"active"},{"id":"nct03671018","name":"A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma","nct":"NCT03671018","phase":"1/2","status":"active"},{"id":"nct04077723","name":"A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combi","nct":"NCT04077723","phase":"1/2","status":"active"},{"id":"nct03533283","name":"An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma","nct":"NCT03533283","phase":"1/2","status":"active"},{"id":"nct03564340","name":"Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent","nct":"NCT03564340","phase":"1/2","status":"recruiting"},{"id":"nct04691817","name":"Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based T","nct":"NCT04691817","phase":"1/2","status":"recruiting"}],"pathways":[],"companies":["johnson-johnson","recordati","roche-genentech"],"keyPapers":["paper-ohlund-caf-subtypes-mycaf-icaf-jem-2017","paper-grivennikov-immunity-inflammation-cancer-cell-2010"],"hotspots":[],"openQuestions":[],"assays":[],"resistance":[],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}